Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like 2019 in Review: A Flurry of Major Drug Mergers and Acquisitions December 25, 2019 Gilead’s Veklury Approved for Pediatric COVID-19 Patients Under 12 April 25, 2022 White House Planning to Cut Non-Defense Spending by $54 Billion March 1, 2017